Talphera (TLPH) Stock Price, News & Analysis

Company Overview

Talphera, Inc. (NASDAQ: TLPH) is a specialty pharmaceutical company focused on developing and commercializing therapies for acute pain management. The company’s primary commercial product is DSUVIA, a sublingual tablet containing sufentanil, a potent opioid analgesic designed for use in medically supervised healthcare settings.

DSUVIA is approved in the United States for the management of acute pain in adults that is severe enough to require an opioid analgesic. The product is administered under the supervision of a healthcare professional using a single-dose applicator and is intended for settings such as hospitals, surgical centers and other qualified healthcare environments. Because of its potency and safety requirements, DSUVIA is not intended for home use.

The company was formerly known as AcelRx Pharmaceuticals and adopted the Talphera name as part of its focus on acute pain treatments. Talphera has also developed other sufentanil-based delivery technologies, including the Zalviso sublingual tablet system, which was designed for patient-controlled pain management in hospital settings and has been evaluated in markets outside the United States.

Talphera’s operations are primarily focused on the U.S. healthcare market, with its products and development programs centered on hospital-based and medically supervised pain care. Vincent Angotti has served as the company’s chief executive officer.

Key Stats

• Today's Range: $1.16 to $1.18
• 50-Day Range: $1.16 to $1.47
• 52-Week Range: $0.69 to $1.57
• Volume: 79,498 shs
• Average Volume: 123,754 shs
• Market Capitalization: $60.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

Talphera Stock Analysis - MarketRank™

Talphera scored higher than 39% of companies evaluated by MarketBeat, and ranked 636th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Talphera has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Talphera has a consensus price target of $3.00, representing about 158.6% upside from its current price of $1.16.

Amount of Analyst Coverage

Talphera has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Talphera are expected to decrease in the coming year, from ($0.23) to ($0.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Talphera is -4.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Talphera is -4.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Talphera has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.02% of the float of Talphera has been sold short.

Short Interest Ratio / Days to Cover

Talphera has a short interest ratio ("days to cover") of 2.18, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Talphera has recently decreased by 1.27%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Talphera does not currently pay a dividend.

Dividend Growth

Talphera does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for TLPH on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

MarketBeat Follows

1 people have added Talphera to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Talphera insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.50% of the stock of Talphera is held by insiders.

Percentage Held by Institutions

37.67% of the stock of Talphera is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:TLPH
• Previous Symbol: NASDAQ:TLPH
• CIK: 1427925
• Web: talphera.com
• Phone: 650-216-3500
• Fax: 650-216-6500
• Employees: 12
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Talphera: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: +158.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.29 million
• Net Margins: N/A
• Pretax Margin: -1,507,599.88%
• Return on Equity: -87.28%
• Return on Assets: -51.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.29
• Quick Ratio: 4.29

Sales & Book Value

• Annual Sales: $1 thousand
• Price / Sales: 60,210.96
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.37 per share
• Price / Book: 3.14

Miscellaneous

• Outstanding Shares: 51,906,000
• Free Float: 50,089,000
• Market Cap: $60.21 million
• Optionable: Optionable
• Beta: 0.69